AZD0120 not checked

AstraZeneca · GC012F

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
10 active
10 in total · 3 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Arm A: AZD0120 - autologous BCMA/CD19 dual-targeting CAR-T cells. Participants will receive lymphodepletion conditioning (cyclophosphamide and fludarabine) followed by AZD0120 CAR-T cell infusion.”In the company’s words, NCT07735637 on ClinicalTrials.gov
Tested for
Relapsed Refractory Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Newly Diagnosed Multiple Myeloma, Relapsed/Refractory Multiple Myeloma, Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis, Lupus Erythematosus, Systemic and 6 more
Main trialPhase 3
“This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, and dexamethasone\], PVd \[pomalidomide, bortezomib and dexamethasone\], or Kd \[carfilzomib and dexamethasone\]) in participants with RRMM.”In the company’s words, NCT07391657 on ClinicalTrials.gov
Other names
GC012F

Other drugs for Relapsed Refractory Multiple Myeloma

All 133 drugs for Relapsed Refractory Multiple Myeloma

Coming up9

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials10

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 14 Jun 2028 A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Phase 3Recruiting 2 Nov 2028 A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Phase 3Recruiting 11 Jan 2029 Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Phase 1/2Recruiting 1 Oct 2027 AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Phase 1/2Recruiting 22 Feb 2028 A Study of AZD0120 in Autoimmune Diseases
Phase 1/2Recruiting 1 May 2029 A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Phase 1/2Recruiting 15 Aug 2029 A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
Phase 1Recruiting 26 May 2028 A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Phase 1Recruiting 12 Dec 2028 An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
Phase 3Authorised not given A Phase III Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against BCMA and CD19, Compared with Continuous Standard Therapy in Participants with NDMM Who Are Ineligible to Receive ASCT as Initial Therapy (DURGA-5).
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow AZD0120

Following is part of Solo: you see every change to AZD0120 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in